Cite
HARVARD Citation
Chihara, D. et al. (2016). Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center. British journal of haematology. pp. 80-88. [Online].